FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995239654> ?p ?o ?g. }

• W1995239654 endingPage "225" @default.
• W1995239654 startingPage "219" @default.
• W1995239654 abstract "Objectives Patients with type 2 diabetes have lower intact parathyroid hormone (iPTH) levels when compared with non-diabetics. Patients with metabolic syndrome (MetSyn) have increased iPTH levels than normal subjects. We hypothesized that patients with type 2 diabetes and MetSyn might have higher iPTH levels as compared with those without MetSyn. Methods The study had an observational design. A total of 84 patients with type 2 diabetes and stage 3 to stage 5 chronic kidney disease (CKD) were recruited (male/female, 40/44). Results A total of 59 (70.2%) patients had MetSyn. Progress from stage 3 to stage 5 CKD lead to a significant increase in iPTH levels (P-trend = .018). Patients with diabetes and MetSyn had lower high-density lipoprotein cholesterol (P = .018) and higher waist circumference (P = .019), systolic blood pressure (P = .036), fasting plasma glucose (P = .005), HbA1c levels (P = .012), triglyceride (P < .0001), and iPTH (P = .009) as compared with patients without MetSyn. Serum iPTH was negatively correlated with estimated glomerular filtration rate, as measured by Modification of Diet in Renal Disease formula (r = −0.339, P = .002), serum calcium (r = −0.232, P = .037), glucose (r = −0.240, P = .03), and HbA1c (r = −0.301, P = .04) and was positively correlated with urinary albumin excretion rate (r = +0.225, P = .044). After adjusting for potential confounders, logPTH was higher in patients with MetSyn as compared with those without among type 2 diabetic patients with CKD (P = .039). Conclusions MetSyn might influence iPTH levels in type 2 diabetic patients with stage 3 to 5 CKD. However, it is still debatable whether MetSyn should be taken into account in determining target iPTH levels in type 2 diabetic patients with CKD. Patients with type 2 diabetes have lower intact parathyroid hormone (iPTH) levels when compared with non-diabetics. Patients with metabolic syndrome (MetSyn) have increased iPTH levels than normal subjects. We hypothesized that patients with type 2 diabetes and MetSyn might have higher iPTH levels as compared with those without MetSyn. The study had an observational design. A total of 84 patients with type 2 diabetes and stage 3 to stage 5 chronic kidney disease (CKD) were recruited (male/female, 40/44). A total of 59 (70.2%) patients had MetSyn. Progress from stage 3 to stage 5 CKD lead to a significant increase in iPTH levels (P-trend = .018). Patients with diabetes and MetSyn had lower high-density lipoprotein cholesterol (P = .018) and higher waist circumference (P = .019), systolic blood pressure (P = .036), fasting plasma glucose (P = .005), HbA1c levels (P = .012), triglyceride (P < .0001), and iPTH (P = .009) as compared with patients without MetSyn. Serum iPTH was negatively correlated with estimated glomerular filtration rate, as measured by Modification of Diet in Renal Disease formula (r = −0.339, P = .002), serum calcium (r = −0.232, P = .037), glucose (r = −0.240, P = .03), and HbA1c (r = −0.301, P = .04) and was positively correlated with urinary albumin excretion rate (r = +0.225, P = .044). After adjusting for potential confounders, logPTH was higher in patients with MetSyn as compared with those without among type 2 diabetic patients with CKD (P = .039). MetSyn might influence iPTH levels in type 2 diabetic patients with stage 3 to 5 CKD. However, it is still debatable whether MetSyn should be taken into account in determining target iPTH levels in type 2 diabetic patients with CKD." @default.
• W1995239654 created "2016-06-24" @default.
• W1995239654 creator A5004647379 @default.
• W1995239654 creator A5012317206 @default.
• W1995239654 creator A5030466196 @default.
• W1995239654 creator A5083224820 @default.
• W1995239654 date "2011-05-01" @default.
• W1995239654 modified "2023-10-16" @default.
• W1995239654 title "Targeting Parathyroid Hormone Level in Diabetic Patients With Stage 3 to 5 Chronic Kidney Disease: Does Metabolic Syndrome Matter?" @default.
• W1995239654 cites W1963615039 @default.
• W1995239654 cites W1969851294 @default.
• W1995239654 cites W1987679215 @default.
• W1995239654 cites W2012487475 @default.
• W1995239654 cites W2055864845 @default.
• W1995239654 cites W2058300153 @default.
• W1995239654 cites W2063866334 @default.
• W1995239654 cites W2078383637 @default.
• W1995239654 cites W2113139464 @default.
• W1995239654 cites W2115605720 @default.
• W1995239654 cites W2118310760 @default.
• W1995239654 cites W2121148891 @default.
• W1995239654 cites W2128901304 @default.
• W1995239654 cites W2130297833 @default.
• W1995239654 cites W2345903479 @default.
• W1995239654 cites W2487377689 @default.
• W1995239654 cites W2337109902 @default.
• W1995239654 doi "https://doi.org/10.1053/j.jrn.2010.04.006" @default.
• W1995239654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20650655" @default.
• W1995239654 hasPublicationYear "2011" @default.
• W1995239654 type Work @default.
• W1995239654 sameAs 1995239654 @default.
• W1995239654 citedByCount "3" @default.
• W1995239654 countsByYear W19952396542013 @default.
• W1995239654 countsByYear W19952396542016 @default.
• W1995239654 countsByYear W19952396542022 @default.
• W1995239654 crossrefType "journal-article" @default.
• W1995239654 hasAuthorship W1995239654A5004647379 @default.
• W1995239654 hasAuthorship W1995239654A5012317206 @default.
• W1995239654 hasAuthorship W1995239654A5030466196 @default.
• W1995239654 hasAuthorship W1995239654A5083224820 @default.
• W1995239654 hasConcept C126322002 @default.
• W1995239654 hasConcept C134018914 @default.
• W1995239654 hasConcept C159641895 @default.
• W1995239654 hasConcept C2777180221 @default.
• W1995239654 hasConcept C2778163477 @default.
• W1995239654 hasConcept C2778653478 @default.
• W1995239654 hasConcept C2778913445 @default.
• W1995239654 hasConcept C2780578515 @default.
• W1995239654 hasConcept C2781208988 @default.
• W1995239654 hasConcept C519063684 @default.
• W1995239654 hasConcept C555293320 @default.
• W1995239654 hasConcept C71924100 @default.
• W1995239654 hasConcept C84393581 @default.
• W1995239654 hasConceptScore W1995239654C126322002 @default.
• W1995239654 hasConceptScore W1995239654C134018914 @default.
• W1995239654 hasConceptScore W1995239654C159641895 @default.
• W1995239654 hasConceptScore W1995239654C2777180221 @default.
• W1995239654 hasConceptScore W1995239654C2778163477 @default.
• W1995239654 hasConceptScore W1995239654C2778653478 @default.
• W1995239654 hasConceptScore W1995239654C2778913445 @default.
• W1995239654 hasConceptScore W1995239654C2780578515 @default.
• W1995239654 hasConceptScore W1995239654C2781208988 @default.
• W1995239654 hasConceptScore W1995239654C519063684 @default.
• W1995239654 hasConceptScore W1995239654C555293320 @default.
• W1995239654 hasConceptScore W1995239654C71924100 @default.
• W1995239654 hasConceptScore W1995239654C84393581 @default.
• W1995239654 hasIssue "3" @default.
• W1995239654 hasLocation W19952396541 @default.
• W1995239654 hasLocation W19952396542 @default.
• W1995239654 hasOpenAccess W1995239654 @default.
• W1995239654 hasPrimaryLocation W19952396541 @default.
• W1995239654 hasRelatedWork W1970114012 @default.
• W1995239654 hasRelatedWork W2020170405 @default.
• W1995239654 hasRelatedWork W2023333646 @default.
• W1995239654 hasRelatedWork W2029959808 @default.
• W1995239654 hasRelatedWork W2035484352 @default.
• W1995239654 hasRelatedWork W2068269311 @default.
• W1995239654 hasRelatedWork W2092271911 @default.
• W1995239654 hasRelatedWork W2110966479 @default.
• W1995239654 hasRelatedWork W2161282407 @default.
• W1995239654 hasRelatedWork W2162385374 @default.
• W1995239654 hasVolume "21" @default.
• W1995239654 isParatext "false" @default.
• W1995239654 isRetracted "false" @default.
• W1995239654 magId "1995239654" @default.
• W1995239654 workType "article" @default.